

CURRICULUM VITAE ET STUDIORUM

Name: Ileana Quinto

Education:

1977: Medical Degree (summa cum laude), University of Naples "Federico II", Naples, Italy.

1981: Board in Pediatrics (summa cum laude), University of Naples "Federico II", Naples, Italy.

Academic positions:

1988-1991: Assistant Professor, Department of Biochemistry and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.

1992-2000: Associate Professor of Biochemistry, Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

2001-todate: Full Professor of Biochemistry, Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

International stages:

1976: Pre-doctoral fellow, Head Unit Prof. Jan Neuhard, Institute of Biological Chemistry, Enzyme Division, University of Copenhagen, Copenhagen, Denmark.

1978-1979: Post-doctoral Fellow, Head Unit Bruce N. Ames, Department of Biochemistry, University of California, Berkeley, California, USA.

1981-1982: Research scientist, Head Unit Dr. Dietrich Averbeck, Institut Curie, Section de Biologie, Paris, France.

1983-1986: Research scientist, Head Unit Prof. Miroslav Radman, Département de Biologie Moléculaire, Université Libre de Bruxelles, Rhode-st-Genése, Belgio.

1997-1998: Visiting Professor, Head Unit Dr. Kuan-Teh Jeang, Laboratory of Molecular Microbiology, NIH, NIAID, Bethesda, MD, USA.

1999-2000: Visiting Professor, Head Unit Dr. Antony Fauci, Laboratory of Immunoregulation, NIH, NIAID, Bethesda, MD, USA.

Fellowships:

1976: Fellowship from the Danish Ministry of Education for research in Molecular Biology.

1979-1980: Fellowship from "Lega Italiana per la Lotta contro i Tumori" for research in Molecular Oncology.

1983-1985: Fellowship from the European Communities for research in Molecular Biology.

1997: Fellowship from the Italian National Research Council for research in Molecular Virology.

Awards and achievements:

1986: Award from the European Environmental Mutagen Society for outstanding scientific work in the field of environmental mutagenesis.

1998: Award from the National Institutes of Health, Bethesda, MD, U.S.A., for Research Excellence in Biomedical Research.

1998: Award from the Elisabeth Glaser Pediatric AIDS Foundation, Santa Monica, California, U.S.A., for Research in AIDS vaccine development.

2002-2014: Member of Scientific Expert Board, Ministry of Education, Universities and Research, Italy (D. M. Number 1176 August 8, 2002).

2003-2017: Member of the Scientific Board of PhD Programme in Medical Biotechnologies, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

2007-2011: President of the Research Commission, Faculty of Medicine and Surgery, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

2013 to date: Member of the Scientific Board of PhD Programme in Life Sciences, University of Catanzaro “Magna Graecia”, Catanzaro, Italy.

2015 to date: Member of REPRISE (Register of Expert Peer Reviewers for Italian Scientific Evaluation) for Basic Research and Industrial Innovation, Ministry of Education, Universities and Research, Italy.

Patents:

1999: Metodo di attenuazione stabile di retrovirus HIV-1 e SIV per acquisizione di funzione: sviluppo di un virus vaccino attenuato per l’AIDS. Ministero delle Attività Produttive. Brevetto per Invenzione industriale N. 1326909.

2008: Polypeptide capable of inhibiting HIV-1 transcription and Replication and Uses Thereof. US Patent App.12/252,279. Docket No.: P298-US

Research Funds:

1987-1989: Grant from the Italian Association for Research on Cancer, AIRC (**140 million Italian lire**). Title: “Analysis of spontaneous and carcinogens-induced gene rearrangements in human and murine cell lines”. Principal Investigator.

1990-1992: Grant AIRC (**120 million Italian lire**). Title: “Analysis of molecular events induced by carcinogens in human and murine cell lines”. Principal Investigator.

1990: Grant N. 5206079 from the Ministry of Public Health – National Research Program on AIDS (**110 million Italian lire**). Title: “Regulation of HIV-1 expression by DNA damaging agents”. Principal Investigator.

1991: Grant N. 6208001 from the Ministry of Public Health – National Research Program on AIDS (**110 million Italian lire**). Title: “Regulation of HIV-1 expression by DNA damaging agents”. Principal Investigator.

1992: Grant N. 720496 from the Ministry of Public Health – National Research Program on AIDS (**110 million Italian lire**). Title: “HIV-1 activation by DNA damaging agents”. Principal Investigator.

1993: Grant N. 820605 from the Ministry of Public Health – National Research Program on AIDS (**110 million Italian lire**). Title: “HIV-1 activation by DNA damaging agents”. Principal Investigator.

1994: Grant AIRC (**40 million Italian lire**). Title: “Mechanisms of tumor progression by DNA damaging agents”. Principal Investigator.

1995: Grant N. 930608 from the Ministry of Public Health – National Research Program on AIDS (**100 million Italian lire**). Title: “HIV-1 activation by genotoxic distress”. Principal Investigator.

1996: Grant N. 9403-90 from the Ministry of Public Health – National Research Program on AIDS (**100 million Italian lire**). Title: “Down-regulation of HIV-1 expression and replication”. Principal Investigator.

1997: Grant N. 40A.0.85 from the Ministry of Public Health – National Research Program on AIDS (**100 million Italian lire**). Title: “Down-regulation of HIV-1 expression and replication”. Principal Investigator.

1997: Grant N. PS-22055-23 from Elizabeth Glaser Pediatric AIDS Foundation (**5000 US dollars**). Title: “Models for live-attenuated AIDS virus vaccine”. Principal Investigator.

1998: Grant N. 40B.80 from the Ministry of Public Health – National Research Program on AIDS (**100 million Italian lire**). Title: “Down-regulation of HIV-1 expression and replication”. Principal Investigator.

1999: Grant N. 40C.77 from the Ministry of Public Health – National Research Program on AIDS (**100 million Italian lire**). Title: “Down-regulation of HIV-1 expression and replication”. Principal Investigator.

2000: Grant N. 40D.70 from the Ministry of Public Health – National Research Program on AIDS (**EUR 40000**). Title: “Down-regulation of HIV-1 expression and replication”. Principal Investigator.

Investigator.

2002-04: Grant “Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale”, PRIN, N. 2002067514_004 from the Italian Ministry of University and Research, MIUR (**EUR 50000**). Title: “Role of NF- κ B in neoplastic transformation and development of inhibitory strategies.” Unit Head.

2003: Grant Regione Calabria-Progetto Speciale Ex Art. 12 LSG 502/92 (**EUR 34402**). Title: “Identification of novel tumor markers by the analysis of proteome and epitopes of tumor cells”. Principal Investigator.

2004-07: Grant FIRB-MIUR N. RBAU01HE9X (**EUR 90000**). Title: “Development of inhibitory peptides of NF- κ B and Tat for AIDS therapy”. Principal Investigator.

2004-06: Grant PRIN-MIUR N. 2004055579_005 (**EUR 64300**). Title: “Mechanisms of apoptosis by I κ B proteins”. Unit Head.

2004: Grant N. 40F.65 from the Ministry of Public Health – National Research Program on AIDS (**EUR 45000**). Title: “Down-regulation of HIV-1/SIV expression and replication”. Principal Investigator.

2005: Grant AIRC (**EUR 40000**). Title: “Identification of the UN1 tumor antigen associated with breast cancer”. Principal Investigator.

2005-10: Grant FIRB-MIUR N. RBLA033WJX_006 (**EUR 386000**). Title: “Costituzione di un laboratorio dedicato all’analisi delle interazioni ligando-recettore mediante biochips di silicio”. Participant.

2006: Grant N. 40G.48 from the Ministry of Public Health – National Research Program on AIDS (**EUR 35000**). Title: “Down-regulation of HIV-1/SIV expression and replication”. Principal Investigator.

2006-08: Grant PRIN-MIUR N. 2006052835_004 (**EUR 55800**). Title: “Role of Btk/IBtk in NF- κ B regulation by B cell receptor”. Unit Head.

2011-13: Grant Programma Operativo Nazionale (PON) “Ricerca e Competitività 2007-2013” N. 01-00862 (**EUR 442500**). Title: “Una piattaforma tecnologica integrata per lo sviluppo di nuovi farmaci per malattie rare” –Project leader: Dompé SpA. Participant.

2011-13: Grant PON “Ricerca e Competitività 2007-2013” N. 01_02782 (**EUR 202500**). Title: “Nuove strategie nanotecnologiche per la messa a punto di farmaci e presidi diagnostici diretti verso cellule cancerose circolanti”- Project leader: BIOGEM Scarl. Participant.

2012-15: Grant PRIN-MIUR N. 2012CK5RPF_002 (**EUR 81844**). Title: "Development and preclinical validation of a nano-technological platform that targets the minimal residual disease in Cancer". Unit Head.

2018-2020: Grant POR CALABRIA FESR-FSE 2014-2020, SIAR number 52461 of 17/02/2017 (**EUR 465949**) Title: “Validazione di nuovi marcatori prognostici della leucemia linfatica cronica”. Project Leader: Diagnostica Bevilacqua. Unit Head.

2018: Grant from the Italian Ministry of University and Research for PhD fellowship in industrial research. Title: “Validazione di nuovi marcatori prognostici della leucemia linfatica cronica”. Scientific director.

2019-2022: Grant PRIN-MIUR N. 2017MHJJ55_002 (**EUR 182710**). Title: “Theranostic nanoparticles based approach targeting a set of microRNAs in drug resistant thyroid and breast cancers”. Unit Head.

Scientific Expertise:

Prof. Ileana Quinto contributed to the advancement of scientific research in the fields of biochemistry, molecular oncology and immunology. She developed original molecular reagents and animal models to study cancer and AIDS pathogenesis. She detailed novel molecular mechanisms of gene expression regulation and cell signalling.

In 1980-1990, she developed new methods for detection of mutagens in prokaryotic and eukaryotic genetic systems. In 1986, she was awarded by the European Environmental Mutagen Society for the

outstanding scientific work in the field of environmental mutagenesis.

In 1990-2000, she focused on AIDS as emergent immune disease. She analysed the HIV-1 and host interactions demonstrating the physical interaction of HIV-1 Tat with I κ B- α repressor and p65 subunit of NF- κ B as relevant mechanism of constitutive NF- κ B activation promoting the HIV-1 expression and replication. Supporting this mechanism, she showed that recombinant HIV-1 and SIVmac239 retroviruses expressing the I κ B- α S32/36A super-repressor of NF- κ B were highly attenuated in cultured primary T-lymphocytes and monocytes, and *in vivo* in Rhesus macaques. She contributed to develop the transgenic Tat-C57BL/6 mouse, which showed thymus atrophy, maturation block of thymic subpopulations and abnormal acute inflammatory response to LPS as consequence of the constitutive NF- κ B activation by Tat. These findings pointed to Tat as pro-inflammatory HIV-1 protein promoting the constitutive NF- κ B activation and immune dysregulation in AIDS. She contributed to identify a set of HIV-1 epitopes recognized by immunoglobulins of long-term non-progressor AIDS patients using phage display libraries. Vaccination of Rhesus macaques with the phage-displayed HIV-1 epitopes conferred protection against disease progression from pathogenic SHIV-89.6PD. These results demonstrated that antibodies against specific HIV-1 epitopes could confer AIDS immune protection.

From 2000 today, Prof. Quinto has focused on tumor biology and B cell receptor (BCR) signalling. She identified the tumor antigen UN1 as glycosylated isoforms of CD43, which are peculiarly associated with different human cancers and tumor progression. She contributed to the physical and functional characterization of the *Inhibitor of Bruton's tyrosine kinase (IBTK)* gene, expressing the Ibtka protein as substrate receptor of the Cul-3 ubiquitin ligase complex. She addressed the role of *IBTK* in cancer. *IBTK* silencing by RNA interference was shown to affect the human transcriptome in cell-specific manner. *IBTK* haploinsufficiency increased the expression of angiogenic cytokines and the vascularization of lymphomas in the *E μ -myc* transgenic mouse, a model of Myc-dependent B-lymphomagenesis. The knockout of *IBTK* gene caused the apoptosis of tumor B-cell lines and pre-cancerous primary B-lymphoma cells, and delayed the onset of lymphomas in *E μ -myc* mice. Consistently with the requirement of *IBTK* for tumor B-cell survival, the expression of IBtka was up regulated in chronic lymphocytic leukemia (CLL) primary cells in disease progression, and down regulated in disease remission after therapy. This evidence defined IBtka as novel marker of CLL aggressiveness.

Prof. Quinto is recently involved in novel experimental approaches for tumor targeting and drug delivery. In particular, she is developing peptide ligands of the antigenic determinants of tumor IgBCRs of chronic lymphocytic leukemia for monitoring tumor B-cell subpopulations in peripheral blood. The peptide ligands for IgBCR will be used for clusterization of CLL patients based on epitope recognition and tumor aggressiveness. This experimental approach could provide new insights into the role of IgBCRs in CLL pathogenesis.

The list of publications includes peer-reviewed international journals with high impact factor, such as Nature Medicine, Nature Immunology, Journal of Experimental Medicine, Blood, Journal of Biological Chemistry, Journal of Virology, Nucleic Acids Research, Retrovirology, PLoS One, Mutation Research, Proteomics, Scientific Reports, Oncotarget, Laekemia, Molecular Cancer, Cell Death and Disease, International Journal of Molecular Sciences.

Referee Expertise:

Prof. Quinto is referee of several scientific journals in the fields of Biochemistry, Cell Biology and Immunology. She has evaluated research projects in Health and Biological Sciences Programs granted by the following national and international agencies:

- Istituto Superiore della Sanità, Ministry of Health, Italy (National Research Program on AIDS,

1988-2006).

- Ministry of Education, Universities and Research, Italy (FIRB, PRIN, SIR, POR, 1992-todate).
- Ministry of Productive Activities, Italy (PIA Innovazione, 2004-2005).
- Republic of Cyprus and European Union (Framework Programme for Research, Technological Development and Innovation, 2009-2010).

Teaching Expertise:

Prof. Quinto is coordinator of the Course of Biochemistry and Molecular biology at the Medical School of University of Catanzaro "Magna Graecia", enrolling 500 medical students/year. She is mentor of junior academic colleagues, PhD students and medical doctors under specialised training. She currently supervises degree theses and doctoral theses in the area of biochemistry, medical biotechnology, molecular oncology and molecular virology.

Publications:

1. De Lorenzo F, **Quinto I***. I tests di mutagenesi nella valutazione della tossicologia dei farmaci. *In: "Nuovi aspetti di Tossicologia Sperimentale e Clinica"*, C. G. Edizioni Medico-Scientifiche, Torino, 1979, pp. 33-49. *Corresponding author.
2. Martire G, **Quinto I**, De Lorenzo F. Monitoraggio di soggetti accidentalmente esposti a mutageni. *In "Controllo delle sostanze chimiche mutagene e cancerogene"*, Edizioni N. Loprieno, Società Italiana di Microbiologia Applicata, 1980, pp. 79-85.
3. **Quinto I***, Staiano N, Martire G, Friscia GO, Signorini M, de Lorenzo F. Mutagenic epoxide impurities discovered in two new beta-adrenergic blocking agents. *Toxicol Lett.* 1980 Feb; 5(2):109-14. PMID: 6110255. *Corresponding author.
4. **Quinto I**. Mutagenicity of alkylnitrites in the Salmonella test. *Boll Soc Ital Biol Sper.* 1980 Apr 30; 56(8):816-20. PMID: 7004467.
5. De Lorenzo F, **Quinto I**, Belisario A, Della Morte R. Aspetti generali di tossicologia genetica. *In "Argomenti di Tossicologia"*, Edizioni E. Marmo, Napoli, 1981, pp. 259-275.
6. Belisario MA, **Quinto I***, De Lorenzo F. Mutagenicity of twelve imidazole derivatives with trichomonacide activity. *Boll Soc Ital Biol Sper.* 1981 Apr 15; 57(7):805-9. PMID: 7023507. *Corresponding author.
7. Bronzetti G, Esposito A, Pagano G, **Quinto I**. A comparative study on the toxicity and mutagenicity of biphenyl (BP) and diphenyl ether (DPE) in sea urchin, *S. typhimurium* and *S. cerevisiae*. *Mutat Res Environ Mutagen Relat Subj* 1981 Aug; 85(4):233. doi:10.1016/0165-1161(81)90076-5.
8. Loprieno N, Barale R, Zucconi D, de Lorenzo F, Belisario A, Buonocore V, **Quinto I**, Vricella G, Cornetti GM. *In vitro* and *in vivo* short-term mutagenicity studies on diesel particulate and extracts. *Mutat Res Environ Mutagen Relat Subj* 1981 Aug; 85(4): 241. doi:10.1016/0165-1161(81)90092-3.
9. **Quinto I**, Martire G, Vricella G, Riccardi F, Perfumo A, Giulivo R, De Lorenzo F. Screening of 24 pesticides by Salmonella/microsome assay: mutagenicity of benazolin, metoxuron and paraoxon. *Mutat Res Environ Mutagen Relat Subj* 1981 Aug; 85(4): 265. doi:10.1016/0165-1161(81)90139-4.

10. **Quinto I**, De Marinis E. Effects of propineb and dower A on sperm morphology in mice. *Mutat Res Environ Mutagen Relat Subj* 1982 June; 97(3): 215. doi:10.1016/0165-1161(82)90153-4.
11. Averbeck D, **Quinto I**, Papadopoulo D. On the genotoxic activity of photoreactive psoralens of cosmetological interest. In *"Proceedings Conference on the Problems of Toxicology of Cosmetic Products"*, Edizioni N. Loprieno, Tirrenia (Pisa), 1982, pp. 45-61.
12. Pagano G, Esposito A, Giordano GG, Vamvakinos E, **Quinto I**, Bronzetti G, Bauer C, Corsi C, Nieri R, Ciajolo A. Genotoxicity and teratogenicity of diphenyl and diphenyl ether: a study of sea urchins, yeast, and Salmonella typhimurium. *Teratog Carcinog Mutagen*. 1983;3(4):377-93. PMID: 6138870.
13. **Quinto I**, Averbeck D. Induction of mitotic non-disjunction by furocoumarins plus 365-nm radiation. *Mutat Res Environ Mutagen Relat Subj* 1983 March; 113(3-4): 295. doi:10.1016/0165-1161(83)90133-4
14. **Quinto I***, De Marinis E. Evaluation of Propineb, a dithiocarbamate pesticide, in the mouse-sperm morphology assay. *Mutat Res*. 1983 Dec; 124(3-4):235-40. PMID: 6656825. *Corresponding author.
15. **Quinto I**, De Marinis E. Sperm abnormalities in mice exposed to diesel particulate. *Mutat Res Environ Mutagen Relat Subj* 1984 June; 130(3): 242. doi:10.1016/0165-1161(84)90270-X.
16. **Quinto I**, Averbeck D, Moustacchi E, Moron J. Frameshift mutagenesis in the dark of furocoumarins proposed for photochemotherapy *Mutat Res Environ Mutagen Relat Subj* 1984 June; 130(3): 181. doi:10.1016/0165-1161(84)90150-X.
17. **Quinto I***, Averbeck D, Moustacchi E, Hrisoho Z, Moron J. Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. *Mutat Res*. 1984 Apr; 136(1):49-54. PMID: 6371513. *Corresponding author.
18. Averbeck D, Papadopoulo D, **Quinto I**. Mutagenic effects of psoralens in yeast and V79 Chinese hamster cells. *Natl Cancer Inst Monogr*. 1984 Dec; 66:127-36. PMID: 6397690.
19. **Quinto I**, Tenenbaum L, Caillet-Fauquet P, Radman M. Quantitative correlation between carcinogenic potencies and mutagenic, recombinogenic and SOS inducer potencies measured in an *E. coli* test system. *Cahiers de Medecine du Travail*. 1986; 23: 124-5.
20. Esposito C, Della Morte R, Micallo G, **Quinto I**, Staiano N. Effects of Mesna on the in vitro and in vivo activation of cyclophosphamide to mutagenic metabolites. *It. J. Ped. Surg. Sci*. 1987 Dec; 1(3): 29-32.
21. **Quinto I**, Avena I, Della Morte R, Staiano N. The *E. coli* multitest: a new bacterial test for genotoxic risk assessment. *Ital J Biochem*. 1987 Sep-Oct; 36(5): 285A-353A. PMID: 3429211.
22. **Quinto I***, Radman M. Carcinogenic potency in rodents versus genotoxic potency in *E. coli*: a correlation analysis for bifunctional alkylating agents. *Mutat Res*. 1987 Dec; 181(2):235-42. PMID: 3317026. *Corresponding author.

23. Pagano G, Cipollaro M, Corsale G, Della Morte R, Esposito A, Giordano G, Micallo G, **Quinto I**, Staiano N. Comparative toxicity of diphenyl, diphenyl ether and some of their hydroxyderivatives. *Medicine Biologie Environment* 1988; 16: 291-7.
24. **Quinto I***, Avena I, Della Morte R, Staiano N, Radman M. Further validation of the *E. coli* multitest: *in vitro* and *in vivo* metabolic activation of procarcinogens. *Mutat Res Environ Mutagen Relat Subj* 1988 June; 203(3): 228-229. doi:10.1016/0165-1161(88)90165-3.
25. **Quinto I**. Sistemi inducibili di riparazione: il sistema SOS. In "*Riparazione del DNA, Mutagenesi e Cancerogenesi*". Babudri N e S. Bonatti S Eds, Cortona, 1988, pp. 15-19
26. **Quinto I***, De Marinis E, De Dominicis G, Della Morte R, Staiano N. Induction of sperm abnormalities in mice by ifosfamida and trofosfamida. *Mutat Res.* 1988 Sep; 201(1): 113-6. PMID: 3419442. *Corresponding author.
27. Tenenbaum L, **Quinto I**, Faelen M. The *E. coli* multitest: a set of strains to characterize diverse genotoxic effects. *Mutat Res.* 1988 Dec; 203(6):415-26. PMID: 2973564.
28. **Quinto I***, De Marinis E, Mallardo M, Arcucci A, Della Morte R, Staiano N. Effect of DNOC, Ferbam and Imidan exposure on mouse sperm morphology. *Mutat Res.* 1989 Dec; 224(4):405-8. PMID: 2555709. *Corresponding author.
29. **Quinto I**, Ruocco MR, Mallardo M, Arcucci A, Venuta S, Scala G. Autocrine growth function of interleukin-1 and interleukin-6 molecules on human transformed B cells. *Farmaci & Terapia* 1989; 6: 66-70.
30. **Quinto I***, Tenenbaum L, Radman M. Genotoxic potency of monofunctional alkylating agents in *E. coli*: comparison with carcinogenic potency in rodents. *Mutat Res.* 1990 Feb; 228(2):177-85. PMID: 2405262. *Corresponding author.
31. Scala G, **Quinto I**, Ruocco MR, Arcucci A, Mallardo M, Caretto P, Forni G, Venuta S. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and *in vivo* tumorigenicity. *J Exp Med.* 1990 Jul 1; 172(1):61-8. PMID: 2162905.
32. **Quinto I***, Mallardo M, Ruocco MR, Arcucci A, Scala G. Ultraviolet Mutagenesis. In "*Light, Lasers, and Synchrotron Radiation: a Health Risk Assessment*". Grandolfo M, Rindi A, and Sliney DH Eds. Plenum Press, New York, USA, 1991, pp. 247-258 *Corresponding author
33. Scala G, **Quinto I**, Ruocco MR, Mallardo M, Squitieri B, Venuta S. Induction of tumorigenicity and plasmacytoid differentiation in EBV-B cells by expression of exogenous interleukin-6 or IL-6 receptor genes. *Leukemia.* 1992; 6 Suppl 3:26S-29S. PMID: 1318473.
34. **Quinto I***, Scala G, Mallardo M, Arcucci A, Ruocco MR, De Lorenzo F. Spontaneous and mutagen-mediated amplification of a neo gene integrated at different genomic sites in rat 2 fibroblasts. *Carcinogenesis.* 1992 Mar; 13(3):439-45. PMID: 1547535. *Corresponding author.
35. Scala G, **Quinto I**, Ruocco MR, Mallardo M, Ambrosino C, Squitieri B, Tassone P, Venuta S. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. *J Virol.* 1993 May; 67(5):2853-61. PMID: 8386279.

36. **Quinto I***, Ruocco MR, Baldassarre F, Mallardo M, Dragonetti E, Scala G. The human immunodeficiency virus type 1 long terminal repeat is activated by monofunctional and bifunctional DNA alkylating agents in human lymphocytes. *J Biol Chem.* 1993 Dec 15; 268(35):26719-24. PMID: 8253807. *Corresponding author.
37. Scala G, **Quinto I**, Ruocco MR, Mallardo M, Ambrosino C, Baldassarre F, Giordano V, Venuta S. Molecular mechanisms of the development of EBV-related B lymphomas: functional cooperation of EBV with IL-6 and HIV-1. *In: "Pathogenicity of Human Herpesviruses due to specific pathogenicity genes"*. Becker Y and Daray G Eds. Springer-Verlag Press, Berlin Heidelberg, Germany, 1994, pp. 298-311.
38. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, Dragonetti E, **Quinto I**, Venuta S. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. *J Exp Med.* 1994 Mar 1; 179(3):961-71. PMID: 8113688.
39. Mallardo M, Giordano V, Dragonetti E, Scala G, **Quinto I***. DNA damaging agents increase the stability of interleukin-1 alpha, interleukin-1 beta, and interleukin-6 transcripts and the production of the relative proteins. *J Biol Chem.* 1994 May 27; 269(21):14899-904. PMID: 8195120. *Corresponding author.
40. Baldassarre F, Mallardo M, Mezza E, Scala G, **Quinto I***. Regulation of NF- κ B through the nuclear processing of p105 (NF-kappa B1) in Epstein-Barr virus-immortalized B cell lines. *J Biol Chem.* 1995 Dec 29; 270(52):31244-8. PMID: 8537390. *Corresponding author.
41. Mallardo M, Dragonetti E, Baldassarre F, Ambrosino C, Scala G, **Quinto I***. An NF- κ B site in the 5'-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF- κ B-activating stimuli. *J Biol Chem.* 1996 Aug 23; 271(34): 20820-7. PMID: 8702837. *Corresponding author.
42. Ruocco MR, Chen X, Ambrosino C, Dragonetti E, Liu W, Mallardo M, De Falco G, Palmieri C, Franzoso G, **Quinto I**, Venuta S, Scala G. Regulation of HIV-1 long terminal repeats by interaction of C/EBP(NF-IL6) and NF- κ B/Rel transcription factors. *J Biol Chem.* 1996 Sep 13; 271(37):22479-86. PMID: 8798413.
43. Chen X, Liu W, **Quinto I**, Scala G. High efficiency of site-directed mutagenesis mediated by a single PCR product. *Nucleic Acids Res.* 1997 Feb 1; 25(3):682-4. PMID: 9016615.
44. Giordano V, De Falco G, Chiari R, **Quinto I**, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G. Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. *J Immunol.* 1997 May 1; 158(9):4097-103. PMID: 9126968.
45. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, **Quinto I**, Venuta S, Scala G. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. *J Biol Chem.* 1997 Jun 6; 272(23):14883-92. PMID: 9169458.
46. Chen X, Liu W, Ambrosino C, Ruocco MR, Poli V, Romani L, **Quinto I**, Barbieri S, Holmes KL, Venuta S, Scala G. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPbeta. *Blood.* 1997 Jul 1; 90(1):156-64. PMID: 9207449.

47. Vajro P, Lucariello S, Migliaro F, Iorio R, **Quinto I**, Vegnente A, Scala G, Sokal E. Monitoring of viremia and replicative status of Epstein Barr virus is useful for early diagnosis and modulation of therapy of lymphoproliferative disease in liver-transplant recipients. *J Pediatr Gastroenterol Nutr* 1998 May; 26(5): 585. doi: 10.1097/00005176-199805000-00206.
48. **Quinto I***, Mallardo M, Baldassarre F, Scala G, Englund G, Jeang KT. Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF- κ B (I κ B- α S32/36A) and the implications for vaccine development. *J Biol Chem*. 1999 Jun 18; 274(25):17567-72. PMID: 10364191. *Corresponding author.
49. Vajro P, Lucariello S, Migliaro F, Sokal E, Gridelli B, Vegnente A, Iorio R, Smets F, **Quinto I**, Scala G. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. *J Infect Dis*. 2000 Jun; 181(6):2050-4. PMID: 10837191.
50. Liu W, **Quinto I**, Chen X, Palmieri C, Rabin RL, Schwartz OM, Nelson DL, Scala G. Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. *Nat Immunol*. 2001 Oct; 2(10):939-46. PMID: 11577348.
51. Chen X, Scala G, **Quinto I**, Liu W, Chun TW, Justement JS, Cohen OJ, vanCott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, Fauci AS. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. *Nat Med*. 2001 Nov; 7(11):1225-31. PMID: 11689887
52. Chen X, Liu W, **Quinto I**, Scala G. Site-directed mutagenesis mediated by a single polymerase chain reaction product. *Methods Mol Biol*. 2002; 182:67-70. PMID: 11768976.
53. Palmieri C, Trimboli F, Scala G, Quinto I, Bressler PB. Regulation of the HIV promoter/enhancer. *Curr Protoc Immunol*. 2003 May; Chapter 12:Unit 12.7. doi: 10.1002/0471142735.im1207s54. PMID: 18432898.
54. Ambrosino C, Palmieri C, Puca A, Trimboli F, Schiavone M, Olimpico F, Ruocco MR, di Leva F, Toriello M, **Quinto I**, Venuta S, Scala G. Physical and functional interaction of HIV-1 Tat with E2F-4, a transcriptional regulator of mammalian cell cycle. *J Biol Chem*. 2002 Aug 30; 277(35):31448-58. PMID: 12055184.
55. **Quinto I***, Puca A, Greenhouse J, Silvera P, Yalley-Ogunro J, Lewis MG, Palmieri C, Trimboli F, Byrum R, Adelsberger J, Venzon D, Chen X, Scala G. High attenuation and immunogenicity of a simian immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF- κ B. *J Biol Chem*. 2004 Jan 16; 279(3):1720-8. PMID: 14593121. *Corresponding author.
56. Palmieri C, Trimboli F, Puca A, Fiume G, Scala G, **Quinto I***. Inhibition of HIV-1 replication in primary human monocytes by the I κ B- α S32/36A repressor of NF- κ B. *Retrovirology*. 2004 Dec 21; 1:45. PMID: 15613239. *Corresponding author.
57. de Laurentiis A, Caterino M, Orrù S, Ruoppolo M, Tuccillo F, Masullo M, **Quinto I**, Scala G, Pucci P, Palmieri C, Tassone P, Salvatore F, Venuta S. Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein. *Int J Biol Macromol*. 2006 Aug 15; 39(1-3):122-6. PMID: 16580720.

58. Puca A, Fiume G, Palmieri C, Trimboli F, Olimpico F, Scala G, **Quinto I***. I κ B- α represses the transcriptional activity of the HIV-1 Tat transactivator by promoting its nuclear export. *J Biol Chem*. 2007 Dec 21; 282(51):37146-57. PMID: 17942396. *Corresponding author.
59. Schiavone M, **Quinto I**, Scala G. Perspectives for a protective HIV-1 vaccine. *Adv Pharmacol*. 2008; 56:423-52. PMID: 18086420.
60. Spatuzza C, Schiavone M, Di Salle E, Janda E, Sardiello M, Fiume G, Fierro O, Simonetta M, Argiriou N, Faraonio R, Capparelli R, **Quinto I***, Scala G. Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk. *Nucleic Acids Res*. 2008 Aug; 36(13):4402-16. doi: 10.1093/nar/gkn413 PMID: 18596081. *Corresponding author.
61. Iaccino E, Schiavone M, Fiume G, **Quinto I**, Scala G. The aftermath of the Merck's HIV vaccine trial. *Retrovirology*. 2008 Jul 2; 5:56. doi: 10.1186/1742-4690-5-56. PMID: 18597681.
62. Rosati A, Di Salle E, Luberto L, **Quinto I**, Scala G, Turco MC, Pascale M. Identification of a Btk-BAG3 complex induced by oxidative stress. *Leukemia*. 2009 Apr;23(4):823-4. doi: 10.1038/leu.2009.23. PMID: 19212330.
63. Fiume G, Rossi A, Di Salle E, Spatuzza C, Mallardo M, Scala G, **Quinto I***. Computational analysis and *in vivo* validation of a microRNA encoded by the IBTK gene, a regulator of B-lymphocytes differentiation and survival. *Comput Biol Chem*. 2009 Dec; 33(6):434-9. doi: 10.1016/j.compbiolchem.2009.08.001. PMID: 19782003. *Corresponding author.
64. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico MR, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, **Quinto I**, Scala G. *In vivo* targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder. *Blood*. 2010 Jul 15; 116(2):226-38. doi: 10.1182/blood-2009-11-253617. PMID: 20363775.
65. de Laurentiis A, Gaspari M, Palmieri C, Falcone C, Iaccino E, Fiume G, Massa O, Masullo M, Tuccillo FM, Roveda L, Prati U, Fierro O, Cozzolino I, Troncone G, Tassone P, Scala G, **Quinto I***. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. *Mol Cell Proteomics*. 2011 May; 10(5):M111.007898. doi: 10.1074/mcp.M111.007898. PMID: 21372249. *Corresponding author.
66. Janda E, Palmieri C, Pisano A, Pontoriero M, Iaccino E, Falcone C, Fiume G, Gaspari M, Nevolo M, Di Salle E, Rossi A, De Laurentiis A, Greco A, Di Napoli D, Verheij E, Britti D, Lavecchia L, **Quinto I***, Scala G. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtk. *Blood*. 2011 Jun 16; 117(24):6520-31. doi: 10.1182/blood-2010-09-308080. PMID: 21482705. *Corresponding author.
67. Vitagliano L, Fiume G, Scognamiglio PL, Doti N, Cannavò R, Puca A, Pedone C, Scala G, **Quinto I***, Marasco D. Structural and functional insights into I κ B- α /HIV-1 Tat interaction. *Biochimie*. 2011 Sep; 93(9):1592-600. doi: 10.1016/j.biochi.2011.05.025. PMID: 21664225. *Corresponding author.
68. Fiume G, Vecchio E, De Laurentiis A, Trimboli F, Palmieri C, Pisano A, Falcone C, Pontoriero M, Rossi A, Scialdone A, Fasanella Masci F, Scala G, **Quinto I***. Human immunodeficiency virus-

1 Tat activates NF- κ B via physical interaction with I κ B- α and p65. *Nucleic Acids Res.* 2012 Apr; 40(8):3548-62. doi: 10.1093/nar/gkr1224. PMID: 22187158. *Corresponding author.

69. Schiavone M, Fiume G, Caivano A, de Laurentiis A, Falcone C, Masci FF, Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Rossi A, Scialdone A, Vecchio E, Andreozzi C, Trovato M, Rafay J, Ferko B, Montefiori D, Lombardi A, Morsica G, Poli G, **Quinto I**, Pavone V, de Berardinis P, Scala G. Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. *Int J Mol Sci.* 2012; 13(5):5674-99. doi: 10.3390/ijms13055674. PMID: 22754323.

70. Causa F, Della Moglie R, Iaccino E, Mimmi S, Marasco D, Scognamiglio PL, Battista E, Palmieri C, Cosenza C, Sanguigno L, **Quinto I**, Scala G, Netti PA. Evolutionary screening and adsorption behavior of engineered M13 bacteriophage and derived dodecapeptide for selective decoration of gold interfaces. *J Colloid Interface Sci.* 2013 Jan 1; 389(1):220-9. doi: 10.1016/j.jcis.2012.08.046. PMID: 23031494.

71. Fiume G, Rossi A, de Laurentiis A, Falcone C, Pisano A, Vecchio E, Pontoriero M, Scala I, Scialdone A, Masci FF, Mimmi S, Palmieri C, Scala G, **Quinto I***. Eukaryotic Initiation Factor 4H is under transcriptional control of p65/NF- κ B. *PLoS One.* 2013 Jun 11;8(6):e66087. doi: 10.1371/journal.pone.0066087. PMID: 23776612. *Corresponding author.

72. Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, Tassone P, Scala I, Buonaguro FM, **Quinto I***, Scala G. Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43. *Biomed Res Int.* 2014;2014:742831. Review. PMID: 24689054. *Corresponding author.

73. Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C, Iaccino E, Galandrini R, Capuano C, Santoni A, D'Armiento FP, Arra C, Barbieri A, Dal Piaz F, Venzon D, Bonelli P, Buonaguro FM, Scala I, Mallardo M, **Quinto I***, Scala G. Cancer-Associated CD43 Glycoforms as Target of Immunotherapy. *Mol Cancer Ther.* 2014 Mar;13(3):752-62. doi: 10.1158/1535-7163.MCT-13-0651. PMID: 24356816. *Corresponding author.

74. Migliaccio N, Palmieri C, Ruggiero I, Fiume G, Martucci NM, Scala I, **Quinto I**, Scala G, Lamberti A, Arcari P. B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy. *Cancer Cell Int.* 2015 May 7;15:50. doi: 10.1186/s12935-015-0202-4. eCollection 2015. PMID: 25983658.

75. Pisano A, Ceglia S, Palmieri C, Vecchio E, Fiume G, de Laurentiis A, Mimmi S, Falcone C, Iaccino E, Scialdone A, Pontoriero M, Masci FF, Valea R, Krishnan S, Gaspari M, Cuda G, Scala G, **Quinto I***. CRL3IBTK Regulates the Tumor Suppressor Pcd4 through Ubiquitylation Coupled to Proteasomal Degradation. *J Biol Chem.* 2015 May 29;290(22):13958-71. doi: 10.1074/jbc.M114.634535. PMID: 25882842. *Corresponding author.

76. Fiume G, Scialdone A, Albano F, Rossi A, Maria Tuccillo F, Rea D, Palmieri C, Caiazzo E, Cicala C, Bellevicine C, Falcone C, Vecchio E, Pisano A, Ceglia S, Mimmi S, Iaccino E, Laurentiis Ad, Pontoriero M, Agosti V, Troncone G, Mignogna C, Palma G, Arra C, Mallardo M, Maria Buonaguro F, Scala G, **Quinto I***. Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice. *Sci Rep.* 2015 Sep 7;5:13864. doi: 10.1038/srep13864. PMID: 26343909. *Corresponding author.

77. Fiume G, Scialdone A, Rizzo F, De Filippo MR, Laudanna C, Albano F, Golino G, Vecchio E, Pontoriero M, Mimmi S, Ceglia S, Pisano A, Iaccino E, Palmieri C, Paduano S, Viglietto G, Weisz A, Scala G, **Quinto I***. IBTK Differently Modulates Gene Expression and RNA Splicing in HeLa

and K562 Cells. *Int J Mol Sci.* 2016 Nov 7;17(11). pii: E1848. PMID: 27827994. *Corresponding author.

78. Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, Chiurazzi F, Fiume G, Pisano A, Ceglia S, Pontoriero M, Golino G, Tassone P, **Quinto I***, Scala G, Palmieri C. Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. *Leukemia.* 2016 Dec;30(12):2419-2422. doi: 10.1038/leu.2016.245. PMID:27568521. *Corresponding author.

79. Mangini M, Iaccino E, Mosca MG, Mimmi S, D'Angelo R, **Quinto I***, Scala G, Mariggì S. Peptide-guided targeting of GPR55 for anti-cancer therapy. *Oncotarget.* 2017 Jan 17;8(3):5179-5195. doi: 10.18632/oncotarget.14121. PMID: 28029647 *Corresponding author.

80. Iaccino E, Mimmi S, Dattilo V, Marino F, Candeloro P, Di Loria A, Marimpietri D, Pisano A, Albano F, Vecchio E, Ceglia S, Golino G, Lupia A, Fiume G, **Quinto I***, Scala G. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. *Mol Cancer.* 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8. PMID: 29029605 *Corresponding author.

81. Torino E, Auletta L, Vecchione D, Orlandella FM, Salvatore G, Iaccino E, Fiorenza D, Grimaldi AM, Sandomenico A, Albanese S, Sarnataro D, Gramanzini M, Palmieri C, Scala G, **Quinto I**, Netti PA, Salvatore M, Greco A. Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles. *Nanomedicine.* 2017 Nov 22;14(2):483-491. doi: 10.1016/j.nano.2017.11.016. PMID: 29175599.

82. Albano F, Chiurazzi F, Mimmi S, Vecchio E, Pastore A, Cimmino C, Frieri C, Iaccino E, Pisano A, Golino G, Fiume G, Mallardo M, Scala G, **Quinto I***. The Expression of Inhibitor of Bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukemia conferring resistance to apoptosis. *Cell Death Dis.* 2018 Jan 9;9(1):13. doi: 10.1038/s41419-017-0026-3. PMID: 29317636. *Corresponding author.

83. Manna I, Iaccino E, Dattilo V, Barone S, Vecchio E, Mimmi S, Filippelli E, Demonte G, Polidoro S, Granata A, Scannapieco S, **Quinto I**, Valentino P, Quattrone A. Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. *FASEB J.* 2018 Aug;32(8):4241-4246. doi: 10.1096/fj.201701533R. PMID: 29505299.

84. Pisano A, Albano F, Vecchio E, Renna M, Scala G, **Quinto I***, Fiume G. Revisiting Bacterial Ubiquitin Ligase Effectors: Weapons for Host Exploitation. *Int J Mol Sci.* 2018 Nov 13;19(11). pii: E3576. doi: 10.3390/ijms19113576. PMID: 30428531. * Co-last author.

85. Mimmi S, Maisano D, **Quinto I**, Iaccino E. Phage Display: An Overview in Context to Drug Discovery. *Trends Pharmacol Sci.* 2019 Feb;40(2):87-91. doi: 10.1016/j.tips.2018.12.005. PMID: 30606501.

86. Pontoriero M, Fiume G, Vecchio E, de Laurentiis A, Albano F, Iaccino E, Mimmi S, Pisano A, Agosti V, Giovannone E, Altobelli A, Caiazza C, Mallardo M, Scala G, **Quinto I***. Activation of NF- κ B in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of I κ B- α . *J Mol Med (Berl).* 2019 May;97(5):675-690. doi: 10.1007/s00109-019-01777-x. Epub 2019 Mar 19. PMID: 30887112. *Corresponding author.

87. Vecchio E, Golino G, Pisano A, Albano F, Falcone C, Ceglia S, Iaccino E, Mimmi S, Fiume G, Giurato G, Britti D, Scala G, **Quinto I***. IBTK contributes to B-cell lymphomagenesis in E μ -myc

transgenic mice conferring resistance to apoptosis. *Cell Death Dis.* 2019 Apr 11;10(4):320. doi: 10.1038/s41419-019-1557-6. PMID: 30975981. *Corresponding author.

88. Albano F, Vecchio E, Renna M, Iaccino E, Mimmi S, Caiazza C, Arcucci A, Avagliano A, Pagliara V, Donato G, Palmieri C, Mallardo M, **Quinto I**, Fiume G. Insights into Thymus Development and Viral Thymic Infections. *Viruses.* 2019 Sep 9;11(9). pii: E836. doi: 10.3390/v11090836. PMID: 31505755.

89. Lupia A, Mimmi S, Iaccino E, Maisano D, Moraca F, Talarico C, Vecchio E, Fiume G, Ortuso F, Scala G, **Quinto I***, Alcaro S. Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia. *Eur J Med Chem.* 2020 Jan 1;185:111838. doi: 10.1016/j.ejmech.2019.111838. Epub 2019 Nov 1. PMID: 31718942. *Co-last author and corresponding author.

90. Vecchio E, Fiume G, Mignogna C, Iaccino E, Mimmi S, Maisano D, Trapasso F, **Quinto I***. IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice. *Int J Mol Sci.* 2020 Jan 30;21(3). pii: E885. doi: 10.3390/ijms21030885. PMID:32019112. *Corresponding author.

91. Mimmi S, Maisano D, Nisticò N, Vecchio E, Chiurazzi F, Ferrara K, Iannalfo M, D'Ambrosio A, Fiume G, Iaccino E, **Quinto I***. Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors. *Leukemia.* 2020 Jun 1. doi: 10.1038/s41375-020-0885-y. PMID: 32483301. *Corresponding author.

92. Vecchio E, Fiume G, Correnti S, Romano S, Iaccino E, Mimmi S, Maisano D, Nisticò N, **Quinto I***. Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models. *Int J Mol Sci.* 2020 Jun 15;21(12):4265. doi: 10.3390/ijms21124265. PMID: 32549409. *Corresponding author.

93. Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Maisano D, Mimmi S, Russo R, Fioravanti A, Fiume G, Vecchio E, Nisticò N, **Quinto I***, Iaccino E. *Pharmaceuticals (Basel).* 2020 Aug 4;13(8):180. doi: 10.3390/ph13080180. PMID: 32759810. *Co-last author.

94. Nisticò N, Maisano D, Iaccino E, Vecchio E, Fiume G, Rotundo S, **Quinto I**, Mimmi S. Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival. *Pharmaceuticals (Basel).* 2020 Sep 14;13(9):E244. doi: 10.3390/ph13090244. PMID: 32937811.